NCT03226418 2026-03-10Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaUniversity of NebraskaPhase 2 Completed75 enrolled 14 charts
NCT02286726 2026-03-04CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 2 Completed56 enrolled 11 charts
NCT02975869 2026-03-03A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid LeukemiaMassachusetts General HospitalPhase NA Completed160 enrolled
NCT03358719 2026-02-27DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaRoswell Park Cancer InstitutePhase 1 Completed8 enrolled 9 charts
NCT02730299 2026-02-25Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDSGamida Cell ltdPhase 3 Completed125 enrolled 18 charts 1 FDA
NCT03600155 2026-02-17Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer CenterPhase 1 Completed29 enrolled